Cancer stem cell targeted cancer vaccines
Inventors
Bergstein, Ivan • Brooks, Christopher • Cirrito, Thomas P.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12357678-B2
Publication Date
2025-07-15
Expiration Date
Abstract
Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, and route of administration for the regimens.
Core Innovation
The invention relates to peptide-based cancer stem cell targeted cancer vaccines for treating brain cancer in a subject, including glioma. It targets both cancer stem cells and tumor bulk, using vaccine components that include HLA-A2 restricted CTL epitopes derived from IL-13Rα2, EphA2, and survivin, together with a Tetanus toxoid helper T cell epitope.
The vaccine is formulated as an emulsion and is combined with one or more T cell receptor modulators selected from a defined list of antibodies, fusion proteins/inhibitors, and combinations thereof. The document further describes immunomodulatory agents including GM-CSF and/or imiquimod, and an emulsifier/adjuvant such as Montanide ISA-51, as part of the vaccine formulation concept.
Co-administration with bevacizumab is described in connection with the treating method. The selected antigens are present on CD133+ cancer stem cell subpopulations, and flow cytometry indicates expression of EphA2 and IL-13Rα2 on CD133+ cancer stem-like cells, supporting the cancer stem cell targeted vaccine approach described.
Claims Coverage
The independent claim covers a brain cancer treatment method using an emulsion-formulated peptide pharmaceutical composition and T cell receptor modulators, with co-administration of bevacizumab and exclusion of a peptide consisting of SEQ ID NO: 7. The claim includes four inventive features.
Peptide emulsion vaccine for brain cancer treatment
A method for treating brain cancer comprising administering a pharmaceutical composition formulated as an emulsion that includes an IL-13Ra2 peptide having an amino acid sequence chosen from SEQ ID NOs: 1-4, an EphA2 peptide set forth in SEQ ID NO:5, a survivin peptide set forth in SEQ ID NO:9, and a Tetanus toxoid peptide set forth in SEQ ID NO:10.
T cell receptor modulator combination
The method further comprises administering one or more T cell receptor modulators selected from anti-CD4 antibodies, anti-CD3 antibodies, anti-CD5 antibodies, anti-CD7 antibodies, anti-CD8 antibodies, anti-CD40 ligand monoclonal antibodies, anti-CD52 antibodies, anti-CD2 antibodies, anti-CD11a antibodies, anti-B7 antibodies, CTLA4-immunoglobulin, lymphocyte function-associated antigen-3 T cell inhibitor protein (LFA-3TIP), and combinations thereof.
Exclusion of peptide consisting of SEQ ID NO: 7
The method excludes administering a peptide consisting of SEQ ID NO: 7.
Co-administration with bevacizumab
The method provides that the pharmaceutical composition is co-administered with bevacizumab.
Overall claim coverage centers on an emulsion-formulated peptide vaccine for brain cancer using IL-13Ra2, EphA2, survivin, and Tetanus toxoid peptides, administered with selected T cell receptor modulators, excluding a peptide consisting of SEQ ID NO: 7, and co-administering bevacizumab.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?